Literature DB >> 19858378

Bone marrow fibrosis and diagnosis of essential thrombocythemia.

Juergen Thiele, Hans Michael Kvasnicka, James W Vardiman, Attilio Orazi, Vito Franco, Heinz Gisslinger, Gunnar Birgegard, Martin Griesshammer, Ayalew Tefferi.   

Abstract

Entities:  

Mesh:

Year:  2009        PMID: 19858378     DOI: 10.1200/JCO.2009.24.3485

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

Review 1.  WHO classification of myeloproliferative neoplasms (MPN): A critical update.

Authors:  Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

2.  Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology.

Authors:  Ayalew Tefferi; Pierre Noel; Curtis A Hanson
Journal:  J Mol Diagn       Date:  2011-06-30       Impact factor: 5.568

3.  Subcellular mislocalization of the transcription factor NF-E2 in erythroid cells discriminates prefibrotic primary myelofibrosis from essential thrombocythemia.

Authors:  Konrad Aumann; Anna-Verena Frey; Annette M May; Dieter Hauschke; Clemens Kreutz; Jan P Marx; Jens Timmer; Martin Werner; Heike L Pahl
Journal:  Blood       Date:  2013-05-13       Impact factor: 22.113

4.  [Differential diagnosis of myeloproliferative neoplasms. Quantitative NF-E2 immunohistochemistry for differentiating between essential thrombocythemia and primary myelofibrosis].

Authors:  K Aumann; A-V Frey; A M May; D Hauschke; C Kreutz; J P Marx; J Timmer; M Werner; H L Pahl
Journal:  Pathologe       Date:  2013-11       Impact factor: 1.011

5.  Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium.

Authors:  A Tefferi; O Abdel-Wahab; F Cervantes; J D Crispino; G Finazzi; F Girodon; H Gisslinger; J Gotlib; J-J Kiladjian; R L Levine; J D Licht; A Mullally; O Odenike; A Pardanani; R T Silver; E Solary; T Mughal
Journal:  Blood Cancer J       Date:  2011-03-04       Impact factor: 11.037

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.